The NIH has been without a permanent director since 2025. Now officials announce that acting director John Powers III will ...
It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy. On Tuesday, Sellas ...
Researchers are seeking a sickle cell treatment as effective as gene therapy, without the drawbacks. This entrepreneur thinks ...
CG Oncology's bladder cancer immunotherapy reduced risk of tumor recurrence by 68% — results that may change how physicians ...
Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a ...
Venture capitalist John Doerr on Tom Health, a new AI tool for primary care: "I think this is one of the best possible uses ...
The language around self-care for doctors puts the onus on them to fix themselves. But the system is to blame, writes Frances ...
The Trump administration proposed new regulations Monday that top officials say would “prevent fraud, remove bad actors, and ...
A proposal by the Trump administration to cap the amount of time foreign students and scholars can spend in the country has ...
The acting director of NIAID, John Powers III, will become the permanent director, the agency announced Monday.
The FDA approved a new breast cancer drug from Roche, teeing up the launch of a medicine the company has said could become ...
Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results